On October 14, 2025, Telomir Pharmaceuticals, Inc. announced new lab findings showing that Telomir-1 effectively reduces the viability of aggressive pancreatic cancer cells, emphasizing its potential in treating difficult cancers. The drug's impact on energy metabolism pathways was notable, and further research into other cancer types is planned.